This sample does not contain detectable SARS-CoV-2 antibodies. This negative result does not rule out SARS-CoV-2 infection. Correlation with epidemiologic risk factors and other clinical and laboratory findings is recommended. Serologic results should not be used as the sole basis to diagnose or exclude recent SARS-CoV-2 infection. This assay will not detect antibodies induced by the currently available SARS-CoV-2 vaccines. The current vaccines elicit antibodies specific to the viral spike protein. Labcorp offers two test codes that detect viral spike-specific antibodies: 164090 SARS-CoV-2 Semi-Quantitative Total Antibody, Spike and 164055 SARS-CoV-2 Antibody, IgG, Spike (Qualitative).

Positive results with this SARS-CoV-2 Antibodies, Nucleocapsid assay suggest recent or previous natural infection with SARS-CoV-2.

Comments:

* This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens.
General Comments & Additional Information
Clinical Info: ABNORMAL REPORT

Ordered Items
SARS-CoV-2 Ab, Nucleocapsid

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE</th>
<th>INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2 Ab, Nucleocapsid</td>
<td>Positive</td>
<td>Negative</td>
<td>01</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results suggest recent or prior infection with SARS-CoV-2. Correlation with epidemiologic risk factors and other clinical and laboratory findings is recommended. Serologic results should not be used as the sole basis to diagnose or exclude recent SARS-CoV-2 infection. False positive results infrequently occur due to prior infection with other human Coronaviruses. This assay will not detect antibodies induced by the currently available SARS-CoV-2 vaccines. The current vaccines elicit antibodies specific to the viral spike protein. Labcorp offers two test codes that detect viral spike-specific antibodies: 164090 SARS-CoV-2 Semi-Quantitative Total Antibody, Spike and 164055 SARS-CoV-2 Antibody, IgG, Spike (Qualitative).

Positive results with this SARS-CoV-2 Antibodies, Nucleocapsid assay suggest recent or previous natural infection with SARS-CoV-2.

Comments:

This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens.